SuD,PasalichM,LeeAH,BinnsCW, 2013.Ovarian cancer risk is reduced by prolonged lactation: a case-control study in southern China,Am J Clin Nutr 97 354 -9
SylviaMT,KumarS,DasariP., 2012.-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables,Indian J Pathol Microbiol 55 33 -
HanifM,ZaidiP,KamalS,HameedA, 2009.Institution-based cancer incidence in a local population in Pakistan: nine years data analysis,Asian Pac J Cancer Prev 10 227 -30
KothandaramanN,BajicVB,BrendanPN,HuakCY,KeowPB,RazviK, 2010.E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer,BMC Cancer 10 64 -
TagawaT,MorganR,YenY,MortimerJ, 2012.Ovarian cancer: opportunity for targeted therapy,J Oncol 682480 -
GulAE,KeserSH,BarisikNO,KandemirNO,CakirC,SensuS, 2010.The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas,Diagn Pathol 5 13 -
SchuellB,GruenbergerT,ScheithauerW,ZielinskiC, 2006.HER2/neu protein expression in colorectal cancer,BMC Cancer 6 123 -
BenavidesLC,GatesJD,CarmichaelMG,PatelR,HolmesJP,HuemanMT, 2009.The impact of HER2/neu expression level on response to the E75 vaccine: from,US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 15 2895 -904
DengW,DongWG,ZhanN,LiaoF,WuHX, 2011.Human epidermal growth factor receptor (HER2)/neu expression and gene amplification in colorectal cancer,Afr J Biotechnol 10 16732 -9
HeubleinS,VrekoussisT,MayrD,FrieseK,LenhardM,JeschkeU, 2013.Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR),J Ovarian Res 6 1 -4
HellströmI,GoodmanG,PullmanJ,YangY,HellströmKE, 2001.Overexpression of HER-2 in ovarian carcinomas,Cancer Res 61 2420 -3
VerriE,GuglielminiP,PuntoniM,PerdelliL,PapadiaA,LorenziP, 2005.HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance,Oncology 68 154 -61
PilsD,PinterA,ReibenweinJ,AlfanzA,HorakP,SchmidB, 2007.In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway,Br J Cancer 96 485 -91
MarwahN,BansalC,GuptaS,SinghS,AroraB, 2007.Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions,Indian J Pathol Microbiol 50 489 -92
HogdallEV,ChristensenL,KjaerSK,BlaakaerJ,BockJE,GludE, 2003.Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma,Cancer 98 66 -73
PfistererJ,Du BoisA,BentzEK,KommossF,HarterP,HuoberJ, 2009.Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany,Int J Gynecol Cancer 19 109 -15
SasakiN,KudohK,KitaT,TsudaH,FuruyaK,KikuchiY, 2007.Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma,Journal of Obstetrics and Gynaecology Research 33 17 -23
GoelS,MehraM,YadavA,SharmaM., 2014.A comparative study of HER-2/neu oncogene in benign and malignant ovarian tumors,Int J Sci Stud 2 50 -4
LanitisE,DangajD,HagemannIS,SongDG,BestA,SandaltzopoulosR, 2012.Primary human ovarian epithelial cancer cells broadly express HER2 at immunologicallydetectable levels,PLoS one 7 e49829 -
TuefferdM,CouturierJ,Penault-LlorcaF,Vincent-SalomonA,BroëtP,GuastallaJP, 2007.HER2 status in ovarian carcinomas: a multicenter Gineco study of 320 patients,PloS One 2 e1138 -